These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20539320)
1. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Dou J; Wu Y; Wang J; Zhao F; Chu L; Liu C; Wen P; Hu W; Hu K; He XF; Gu N Cancer Gene Ther; 2010 Oct; 17(10):675-83. PubMed ID: 20539320 [TBL] [Abstract][Full Text] [Related]
2. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine]. Ma J; Wang YL; Hu HM; Fox BA; Si LS Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138 [TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
4. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Aravindaram K; Wang PH; Yin SY; Yang NS Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790 [TBL] [Abstract][Full Text] [Related]
5. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123 [TBL] [Abstract][Full Text] [Related]
6. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells. Wu S; Wang SQ; Zhang J; Tan XY; Liu JN Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379 [TBL] [Abstract][Full Text] [Related]
7. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau. Qi Y; Moyana T; Chen Y; Xiang J Hum Antibodies Hybridomas; 1996; 7(1):21-6. PubMed ID: 8886833 [TBL] [Abstract][Full Text] [Related]
8. [Specifics anti-tumor immunity induced by gene immunization with ectopic hCGbeta encoding gene]. Wang LX; Wu J; Guan QD; Xiong SD Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):316-9. PubMed ID: 12921555 [TBL] [Abstract][Full Text] [Related]
9. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288 [TBL] [Abstract][Full Text] [Related]
11. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679 [TBL] [Abstract][Full Text] [Related]
12. Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF. Wu S; Yuan D; Liu JN; Tan XY Oncol Rep; 2007 Jan; 17(1):129-33. PubMed ID: 17143489 [TBL] [Abstract][Full Text] [Related]
13. Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice. Dou J; Chu L; Zhao F; Tang Q; Zhang A; Zhang L; Wang Y; Li Y; Cao M; Gu N Cancer Biol Ther; 2007 Dec; 6(12):1871-9. PubMed ID: 18059168 [TBL] [Abstract][Full Text] [Related]
14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Huang H; Li F; Gordon JR; Xiang J Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823 [TBL] [Abstract][Full Text] [Related]
16. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related]
18. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395 [TBL] [Abstract][Full Text] [Related]
19. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454 [TBL] [Abstract][Full Text] [Related]
20. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]